Novel therapies with precision mechanisms for type 2 diabetes mellitus
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Novel therapies with precision mechanisms for type 2 diabetes mellitus
Authors
Keywords
-
Journal
Nature Reviews Endocrinology
Volume 17, Issue 6, Pages 364-377
Publisher
Springer Science and Business Media LLC
Online
2021-05-04
DOI
10.1038/s41574-021-00489-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity
- (2021) Steven B. Heymsfield et al. JAMA Network Open
- Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
- (2020) Mark L. Hartman et al. DIABETES CARE
- Incretin combination therapy for the treatment of non-alcoholic steatohepatitis
- (2020) Aimo Kannt et al. DIABETES OBESITY & METABOLISM
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Central Role of Glucokinase in Glucose Homeostasis: A Perspective 50 Years After Demonstrating the Presence of the Enzyme in Islets of Langerhans
- (2019) Franz M. Matschinsky et al. Frontiers in Physiology
- Semaglutide as a promising antiobesity drug
- (2019) Georgios A. Christou et al. Obesity Reviews
- Function and mechanisms of enteroendocrine cells and gut hormones in metabolism
- (2019) Fiona M. Gribble et al. Nature Reviews Endocrinology
- CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2019 EXECUTIVE SUMMARY
- (2019) Alan J. Garber et al. Endocrine Practice
- Antisense Inhibition of Glucagon Receptor by IONIS-GCGRRx Improves Type 2 Diabetes Without Increase in Hepatic Glycogen Content in Patients With Type 2 Diabetes on Stable Metformin Therapy
- (2019) Erin S. Morgan et al. DIABETES CARE
- FGF21 as Modulator of Metabolism in Health and Disease
- (2019) Caterina Tezze et al. Frontiers in Physiology
- 17-OR: Efficacy and Safety of Chiglitazar, a Novel PPARα/γ/d Pan-Agonist, in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Superiority Trial (CMAP)
- (2019) LINONG JI et al. DIABETES
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Synthesis and biological evaluation of novel thienopyrimidine derivatives as diacylglycerol acyltransferase 1 (DGAT-1) inhibitors
- (2019) Dong Jin Hong et al. JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
- 4th ESPT Conference: pharmacogenomics and personalized medicine – research progress and clinical implementation
- (2019) Csilla Sipeky et al. PHARMACOGENOMICS
- 6. Glycemic Targets: Standards of Medical Care in Diabetes—2020
- (2019) DIABETES CARE
- Efficacy and Safety of GPR119 Agonist DS-8500a in Japanese Patients with Type 2 Diabetes: a Randomized, Double-Blind, Placebo-Controlled, 12-Week Study
- (2018) Yuichiro Yamada et al. ADVANCES IN THERAPY
- Native Oxyntomodulin Has Significant Glucoregulatory Effects Independent of Weight Loss in Obese Humans With and Without Type 2 Diabetes
- (2018) Sudha S. Shankar et al. DIABETES
- Antisense Inhibition of Protein Tyrosine Phosphatase 1B With IONIS-PTP-1B Rx Improves Insulin Sensitivity and Reduces Weight in Overweight Patients With Type 2 Diabetes
- (2018) Andres Digenio et al. DIABETES CARE
- Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic β-cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection
- (2018) Xiao-Xue Zhu et al. DIABETES OBESITY & METABOLISM
- MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
- (2018) Philip Ambery et al. LANCET
- Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study
- (2018) Dalong Zhu et al. Lancet Diabetes & Endocrinology
- Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables
- (2018) Emma Ahlqvist et al. Lancet Diabetes & Endocrinology
- A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials
- (2018) Joachim Tillner et al. DIABETES OBESITY & METABOLISM
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
- (2018) DIABETES CARE
- Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETES CARE
- Fasiglifam-Induced Liver Injury in Patients With Type 2 Diabetes: Results of a Randomized Controlled Cardiovascular Outcomes Safety Trial
- (2018) Venu Menon et al. DIABETES CARE
- Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
- (2018) Juan Pablo Frias et al. LANCET
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
- (2018) Adrian F Hernandez et al. LANCET
- Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps
- (2018) Anubha Mahajan et al. NATURE GENETICS
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluating associations between the benefits and risks of drug therapy in type 2 diabetes: a joint modeling approach
- (2018) John M. Dennis et al. Clinical Epidemiology
- Fibroblast Growth Factor 21—Metabolic Role in Mice and Men
- (2017) Harald Staiger et al. ENDOCRINE REVIEWS
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of bimagrumab on thigh muscle volume and composition in men with casting-induced atrophy
- (2017) Daniel S. Rooks et al. Journal of Cachexia Sarcopenia and Muscle
- Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial
- (2017) David R. Clemmons et al. PLoS One
- Understanding the Physiology of FGF21
- (2016) Ffolliott Martin Fisher et al. Annual Review of Physiology
- Unimolecular Polypharmacy for Treatment of Diabetes and Obesity
- (2016) Matthias H. Tschöp et al. Cell Metabolism
- CYP2C8 and SLCO1B1 Variants and Therapeutic Response to Thiazolidinediones in Patients With Type 2 Diabetes
- (2016) Adem Y. Dawed et al. DIABETES CARE
- Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD-6972 in healthy subjects and subjects with type 2 diabetes mellitus
- (2016) Eric G. Vajda et al. DIABETES OBESITY & METABOLISM
- Safety, tolerability, pharmacokinetics and pharmacodynamics of AZP-531, a first-in-class analogue of unacylated ghrelin, in healthy and overweight/obese subjects and subjects with type 2 diabetes
- (2016) S. Allas et al. DIABETES OBESITY & METABOLISM
- Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin
- (2016) Kaixin Zhou et al. NATURE GENETICS
- Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
- (2016) Abd A. Tahrani et al. Nature Reviews Endocrinology
- Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
- (2016) Walter N. Kernan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- AMG 151 (ARRY-403), a novel glucokinase activator, decreases fasting and postprandial glycaemia in patients with type 2 diabetes
- (2015) L. Katz et al. DIABETES OBESITY & METABOLISM
- Imeglimin increases glucose-dependent insulin secretion and improves β-cell function in patients with type 2 diabetes
- (2015) G. Pacini et al. DIABETES OBESITY & METABOLISM
- Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes
- (2015) R. P. Kelly et al. DIABETES OBESITY & METABOLISM
- Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes
- (2015) N. B. Amin et al. DIABETES OBESITY & METABOLISM
- Effects of piragliatin, a glucokinase activator, on fasting and postprandial plasma glucose in patients with type 2 diabetes mellitus
- (2015) Jianguo Zhi et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Sitagliptin Monotherapy
- (2014) Pascale Fouqueray et al. DIABETES CARE
- Effect of Aleglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus
- (2014) A. Michael Lincoff et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults
- (2013) Ralf Nass et al. ANNALS OF INTERNAL MEDICINE
- The Effects of Salsalate on Glycemic Control in Patients With Type 2 Diabetes
- (2013) Allison B. Goldfine ANNALS OF INTERNAL MEDICINE
- Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action
- (2013) Jonathan E. Campbell et al. Cell Metabolism
- The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes
- (2013) Gregory Gaich et al. Cell Metabolism
- Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin
- (2013) J. P. H. Wilding et al. DIABETES OBESITY & METABOLISM
- A Novel Antidiabetic Drug, Fasiglifam/TAK-875, Acts as an Ago-Allosteric Modulator of FFAR1
- (2013) Chiori Yabuki et al. PLoS One
- Severe Hypertriglyceridemia With Pancreatitis
- (2013) Frank M. Sacks et al. JAMA Internal Medicine
- The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
- (2012) P. Fouqueray et al. DIABETES CARE
- Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus
- (2012) L. A. Morrow et al. DIABETES OBESITY & METABOLISM
- Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients
- (2012) V. Pirags et al. DIABETES OBESITY & METABOLISM
- Localisation and composition of skeletal muscle diacylglycerol predicts insulin resistance in humans
- (2012) B. C. Bergman et al. DIABETOLOGIA
- Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study
- (2012) Marina Cuchel et al. LANCET
- Fibroblast growth factor 21: effects on carbohydrate and lipid metabolism in health and disease
- (2011) Susan Kralisch et al. CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE
- Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes
- (2011) G. E. Meininger et al. DIABETES CARE
- Serum FGF-21 Levels in Type 2 Diabetic Patients
- (2011) Xingbo Cheng et al. ENDOCRINE RESEARCH
- Hepatic Glucokinase Expression Is Associated with Lipogenesis and Fatty Liver in Humans
- (2011) Andreas Peter et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Fenofibrate administration does not affect muscle triglyceride concentration or insulin sensitivity in humans
- (2011) Leigh Perreault et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Ghrelin Suppresses Glucose-Stimulated Insulin Secretion and Deteriorates Glucose Tolerance in Healthy Humans
- (2010) J. Tong et al. DIABETES
- Glucokinase-activating GCKR Polymorphisms Increase Plasma Levels of Triglycerides and Free Fatty Acids, but do not Elevate Cardiovascular Risk in the Ludwigshafen Risk and Cardiovascular Health Study
- (2010) D. H. Kozian et al. HORMONE AND METABOLIC RESEARCH
- Piragliatin (RO4389620), a Novel Glucokinase Activator, Lowers Plasma Glucose Both in the Postabsorptive State and after a Glucose Challenge in Patients with Type 2 Diabetes Mellitus: A Mechanistic Study
- (2010) Riccardo C. Bonadonna et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver
- (2009) Nicola L. Beer et al. HUMAN MOLECULAR GENETICS
- Assessing the potential of glucokinase activators in diabetes therapy
- (2009) Franz M. Matschinsky NATURE REVIEWS DRUG DISCOVERY
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Intensive Glucose Lowering in Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes
- (2008) William Duckworth et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started